Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Deborah Collyar: What's In It for Patients?

Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jun
27
Today In Oncology
Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer
First-Line Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors
CNS Prophylaxis With High-Dose Methotrexate in Ultra–High-Risk Large B-Cell Lymphoma
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo